drugset / Trial / NCT04505995
Azacitidine and Homoharringtonine in JMML
Unknown
30 enrolled
Air Force Military Medical University, China
Children's Hospital of Hebei Province · collabQilu Hospital of Shandong University · collabTaian City Central Hospital · collabThe Affiliated Hospital of Qingdao University · collabThe Second Hospital of Hebei Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in children with JMML. The primary objective is to assess the treatment effect on response rate in this subject population.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2023-01-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Homoharringtonine | Small molecule | — | — |